Completed NA INTERVENTIONAL 1-arm NCT00537056

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Sponsor: National Comprehensive Cancer Network

Conditions Carcinoma, Renal Cell Kidney (Renal Cell) Cancer Kidney Neoplasms

Interventions DCE MRI F-18 Fluoro-deoxi-glucose FDG PET CT Gadolinium-DTPA Sunitinib

Updated 7 times since 2017 Last updated: May 12, 2017 Started: Oct 31, 2007 Primary completion: Oct 31, 2011 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00537056, this NA trial focuses on Carcinoma, Renal Cell and Kidney (Renal Cell) Cancer and remains completed. Sponsored by National Comprehensive Cancer Network, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Dec 2021 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Dec 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 2 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed NA
Jan 2017 — Jul 2017 [monthly]

Completed NA

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Comprehensive Cancer Network
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States